Stability of Essential Drugs in Tropical Climates: Zimbabwe - EDM Research Series No. 013
(1994; 86 pages) Ver el documento en el formato PDF
Índice de contenido
Ver el documentoAbbreviations
Ver el documento1. Summary
Abrir esta carpeta y ver su contenido2. Introduction
Abrir esta carpeta y ver su contenido3. Study design and methods
Ver el documento4. Results
Abrir esta carpeta y ver su contenido5. Discussion
Abrir esta carpeta y ver su contenido6. Conclusions and recommendations
Ver el documentoReferences
Cerrar esta carpetaAnnexes
Cerrar esta carpetaAnnex 1: Detailed results for each drug
Ver el documento1.1 Amoxycillin capsules
Ver el documento1.2 Ampicillin capsules
Ver el documento1.3 Acetylsalicylic acid tablets
Ver el documento1.4 Doxycycline capsules
Ver el documento1.5 Ferrous sulfate tablets
Ver el documento1.6 Phenoxymethylpenicillin tablets
Ver el documento1.7 Tetracycline capsules
Ver el documento1.8 Retinol tablets
Ver el documento1.9 Epinephrine injection
Ver el documento1.10 Ampicillin injection
Ver el documento1.11 Benzylpenicillin injection
Ver el documento1.12 Ergometrine injection
Ver el documento1.13 Procaine penicillin injection
Ver el documentoAnnex 2: Validation of laboratory results
 

1.3 Acetylsalicylic acid tablets

SHELF LIFE

Manufacturers A, B, C: 3 years

 

Manufacturer D: 2 years

ASSAY METHOD

Titration method, BP 1988, p.901

 

Contents of 20 capsules mixed; measured three times; mean taken.

ASSAY LIMITS

95 - 105% (BP)

         

SAMPLES OBTAINED

All Manuf.

Manuf. C

Manuf. D

Manuf. A+B

                 

GMS samples

no.

%

no.

%

no.

%

no.

%

Total

16

100

16

100

0

0

0

0

Harare

8

50

           

Bulawayo

8

50

           

Facility samples

             

Total

79

100

59

75

17

22

3

3

Age > 50% SLife

44

56

           

Facility type = PCH

56

71

           

Climate = hot

65

82

           

Transport - slow

54

68

           

Longitudinal series

               

Total

39

100

39

100

0

0

0

0

SUMMARY ASSAY RESULTS

 

All Manuf.

Manuf. C

Manuf. D

GMS samples

no.

%

no.

%

no.

%

Mean age (mths)

 

13.2

 

13.2

   

Mean assay

 

101.1%

 

101.1%

   

95% CL

100.2 - 102.0%

100.2 - 102.0%

   

No. and % fail

0

0%

0

0%

   

Facility samples

All Manuf.

Manuf, C

Manuf. D

Mean age (mths)

 

17.5

 

19.0

 

11.6

Mean assay

 

100.9%

 

101.0%

100.7%

95% CL

100.4 - 101.4%

100.4 - 101.6%

99.9-101.5%

No. and % fail

0

0%

0

0%

0

0%

Longitudinal series

at Manuf.

at GMS

at facility

Mean age (mths)

 

0

11.9

 

18.8

Mean assay

 

100.3%

100.8%

101.1%

95% CL

100.1 - 100.6%

100.2 - 101.3%

100.4 - 101.8%

No. and % fail

0

0%

0

0%

0

0%

 

Mean interval (mths)

6.9

 

Mean loss (-) or gain (+)

+0.4%

 

95% CL for loss/gain

-0.5 + +1.2


Figure 1 - Results of facility samples

Findings:

a) No expired samples were found.

b) Only three samples in total for Manufacturers A and B, all within specifications.

c) All 16 GMS samples for Manufacturers C were within assay limits (mean 101.1%) at mean age 13.2 months.

d) All 79 facility samples were within assay limits (mean 100.9%) at mean age 17.5 months,

e) No consistent loss of potency was found in 39 GMS/facility sample pairs after mean interval 6.9 months.

f) No difference between manufacturers in the facility sample group. g) No initial quality problem was seen.

h) No sign of instability, even in the late part of shelf life.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013